The surge in ELOX shares is primarily due to Oppenheimer raising its price target for the stock, indicating a positive outlook. Additionally, the company's announcement of promising preclinical data for ZKN-157, a potential therapeutic for colorectal cancer, has likely boosted investor confidence. The heavy trading volume and multiple halts for volatility suggest high investor interest and potential for further price movement.